2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Ephrin Receptor
  5. EphB Isoform

EphB

EphB receptors constitute the B-class subgroup of the Eph receptor tyrosine kinase family and mediate contact-dependent cell-cell communication through interactions with transmembrane ephrin-B ligands, thereby regulating tissue patterning, cell positioning, and developmental morphogenesis[1][2]. Mechanistically, EphB-ephrin-B engagement induces bidirectional signaling, including forward signaling in receptor-expressing cells and reverse signaling in ligand-expressing cells, which coordinates cytoskeletal remodeling, cell adhesion, cell repulsion, and directed migration[1][3]. Through these signaling networks, EphB receptors regulate axon guidance, synapse formation, tissue boundary establishment, angiogenesis, and epithelial organization during embryonic and postnatal development[1][2][4]. In disease-associated contexts, dysregulated EphB signaling has been linked to cancer progression, tumor cell migration, angiogenesis, and alterations in tissue homeostasis, although biological outcomes are highly context dependent[5][6]. Compared with related EphA family receptors, EphB receptors preferentially interact with ephrin-B ligands and exhibit distinct functions in neuronal connectivity, vascular specification, and bidirectional signaling mechanisms[1][6]. Among individual isoforms, EphB2 is extensively studied for its roles in excitatory synapse organization and neuronal signaling, whereas EphB4 is particularly associated with vascular development and endothelial cell identity[4][7]. For experimental applications, recombinant ephrin-B-Fc fusion proteins, soluble receptor ectodomains, and EphB-targeting inhibitors or blocking reagents are widely used to manipulate EphB signaling and investigate cell migration, angiogenesis, neural development, and cancer-related mechanisms[5][8].

EphB Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-185227
    EphB4-IN-1
    		Inhibitor
    EphB4-IN-1 is a selective EphB4 tyrosine kinase inhibitor with IC50 values of 0.16-0.30 μM. EphB4-IN-1 binds to the ATP binding site of EphB4 in a DFG-in conformation, forming four stable intermolecular hydrogen bonds. EphB4-IN-1 also inhibits Src, Abl1, Lck, and EGFR kinases. EphB4-IN-1 inhibits EphB4 autophosphorylation. EphB4-IN-1 can be used for the research of cancer, such as non small cell lung cancer.
  • HY-16265A
    JI-101 hydrochloride
    		Inhibitor
    JI-101 hydrochloride is an orally active angiogenesis inhibitor and anticancer agent with 55% oral bioavailability in Sprague Dawley rats, high permeability, and no P-gp substrate activity.JI-101 hydrochloride modulates angiogenesis signaling pathways in tumor vessel beds, downregulates EphB4, targets EphB4, VEGFR-2, and PDGFR-β, and inhibits multiple stages of tumor angiogenesis.JI-101 hydrochloride exerts activity against cancer cells and xenografts, exhibits mild to moderate inhibition of CYP3A4, and shows stability in pre-clinical and human liver microsomes.JI-101 hydrochloride undergoes rapid oral absorption in Sprague Dawley rats, has extensive tissue distribution with preferred lung uptake, and is excreted via bile with mono- and di-hydroxy metabolites, with feces as the primary elimination route.JI-101 hydrochloride can be used for the research of ovarian cancer and solid tumors.
  • HY-10654
    EphB4-IN-2
    		Inhibitor
    EphB4-IN-2 is a tyrosine kinase inhibitor targeting the Eph family and Src family. EphB4-IN-2 binds to the ATP-binding site of the kinase domain of EphB4, and exhibits high affinity for tyrosine kinases with threonine as the gatekeeper residue, such as Abl, Lck and Src. EphB4-IN-2 can be used in research related to tumor-associated angiogenesis.